No clinically relevant electrocardiogram effects in a randomized TQT study of single therapeutic/supratherapeutic rimegepant doses in healthy adults
Abstract A single‐center, phase I, partially double‐blind (double‐blind regarding doses of rimegepant and placebo, and open label with respect to moxifloxacin), randomized, 12‐sequence, four‐period crossover study of therapeutic (75 mg) and supratherapeutic (300 mg) doses of rimegepant with placebo...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Book |
| Published: |
Wiley,
2024-03-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|